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DM II Bugging You? Probiotics May Help Reach Your Glycemic Goals
By Chris Kime PA-S and Kayla Siford PA-S

ABSTRACT:
Objective: To determine the effects of probiotics on glycated hemoglobin (HbA1c) and
fasting blood glucose (FBG) in patients with Type II Diabetes (T2DM) controlled with
oral medications. Design: Systematic Literature Review. Methods: Searches were
conducted on PubMed using the terms: prebiotic, probiotic, type 2 diabetes, non-insulin
dependent, and microbiota. Searches refined with parameters for Randomized Control
Trials, written in English, and available texts. Results: Firouzi et al. did not show a
significant change in the FBG between groups and a decrease in the HbA1c in the
intervention group. Ejtahed et al. showed a significant decrease in both FBG and HbA1c
from the placebo group to the intervention group. Asemi et al. showed that probiotics
prevented a rise in both FBG and decreased HbA1c in the intervention group (though not
significantly). Conclusion: FBG was found to be an inconsistent indicator of the
effectiveness of probiotics for T2DM management. However, HbA1c levels were
consistently lower in the intervention groups compared to control groups. While
statistical significance was shown, clinical significance and extrapolation to a US
population is inconclusive based on this review. The results are promising, but further
studies with longer durations and a US population should be conducted.
INTRODUCTION:
Diabetes is a growing global health crisis that currently affects 463 million adults
world-wide. This number is projected to continue to increase to 578 million people
worldwide by 2030 and then to 700 million by 2045.1 As of 2018, 34.2 million people in
the United States live with diabetes; that’s 10.5% of the population 2.
Prediction and diagnosis of type II diabetes (T2D) utilizes impaired fasting
glucose, impaired glucose tolerance, and glycated hemoglobin (HbA1c) values from
serum. These measures become elevated due to decreased production of insulin, or
decreasing sensitivity to insulin activity. 3 For short term changes, fasting blood glucose
is a better assessor of glucose metabolism. HbA1c measures are less useful in
assessing recent changes in blood glucose but treatment for T2D is focused on
decreasing HbA1c which is a calculation of the mean blood sugar over a period of 8-12
weeks and a better indicator of overall diabetes management.4 Metformin is the most
commonly used first line therapy which has been shown to lower HbA1c by 0.6 to
1.48%.5,6 The CDC reports that 50% of those with diabetes have a HbA1c above 7%, and
29% have a HbA1c above 8%.2 Thus the treatment goal of a HbA1c less than 7% may
be out of reach for many patients receiving monotherapy of Metformin. Many patients

need adjunct therapies to reach their goals and with new research, manipulating the gut
microbiome is a possible method to avoid more pharmaceutical therapy.
With over a thousand species of bacteria, the gut microbiome living in the
intestines has long been known to be an integral part of a person’s health and with the
discovery of the gut-brain access and enteric nervous system, science is just learning
how important a diverse ecosystem can be to managing chronic illnesses. Studies have
found that manipulating the bacteria residing in the gut of those with obesity can help
them lose weight.7 One way to manipulate the gut flora is by introducing probiotics into
the diet. Probiotics are “live microorganisms that confer a health benefit on the host
when administered in adequate amounts.”8 The most commonly used bacteria for
probiotics are various Bifidobacterium and Lactobacillus strains.
The gut microbiome is easily manipulated by the diet a person consumes, and
rightly so, considering that the biome eats whatever we are eating. Poor diets can
decrease the quality and the quantity of the bacteria in the intestines. Studies have
shown that high fat and high fructose diets can disrupt normal gut microflora and lead
to low grade, systemic and chronic inflammation. 8 This inflammation is a precursor to
obesity and T2D, conditions that are also exacerbated by a high sugar diet. Patients
who are obese and/or have T2D have different gut microbiome metabolism by-products
which suggest a different composition of bacteria than patients not suffering from
those conditions.8 Whether the gut microbiome change contributes to the development
of diabetes, or having diabetes changes the composition of bacteria in the gut is not
clear, but there is a difference between the types of bacteria in a “healthy” individual’s
intestines versus a person with diabetes, suggesting the importance of a specific
composition of gut flora.
The presupposition that the composition of the gut microbiome has a direct
relationship to diabetes allows for therapeutic application. Cell line studies indicate
that metabolites of engineered E. coli and Lactobacillus species prevented expression
of inflammatory cytokines and oxidative stress.8 Inflammation and oxidative stress are
implicated in the progression of T2D and present a possible mechanism for
preventative measures. Furthermore, animal studies in diabetic mice show that food
supplemented with certain Lactobacilli species decreased blood glucose and
glycosylated hemoglobin.8
With the promise shown in animal trials of gut microbiome manipulation in T2D,
the efficacy of probiotic therapy has not yet been routinely studied in human trials. This
paper reviews the current studies on using probiotics as adjunct therapy for patients
with T2D who are on oral medications in an effort to determine if probiotic
administration is effective at improving diabetic control by reducing FBG compared to
placebo.

METHODS:
A database search using Pubmed and the MESH terms “prebiotic”, “probiotic”,
“type 2 diabetes”, “non-insulin dependent”, and “microbiota” produced 1060 results. This
number was reduced using the filters to select randomized control trials (RCT), English
language, and full texts. Articles were excluded if the subjects were less than 18 years
old, on insulin therapy, pre-diabetic, diagnosed with type 1 diabetes, pregnant, or using
endpoints that did not include fasting blood glucose and HbA1c. This search resulted in
3 studies which are used in this analysis as outlined in Figure 1.

Figure 1. PRISMA algorithm for the selection of appropriate studies concerning the use of probiotics as
adjunct therapy in adults with type II diabetes.

RESULTS:

Study 1
Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic
control and other diabetes-related outcomes in people with type 2 diabetes: a
randomized control trial. Firouzi et al. 2016.9
Objective
Investigate the effects of multi-strain probiotics on many diabetes related
outcomes in patients with type II diabetes including: glycemic control, lipid profile, blood
pressure, and high-sensitivity C-reactive protein.
Design
This study is a randomized, double-blinded, parallel-group, controlled clinical trial
performed at a diabetes clinic in Kuala Lumpur, Malaysia. A sum of 136 patients were
selected based on a diagnosis of type II diabetes for at least 6 months, no use of insulin
therapy or antibiotics, HbA1c between 6.5 and 12%, FBG less than 15mmol/L, BMI
between 18.5 and 40kg/m2, 3 months of stabile dose of medication, and age 30-70
years. These participants were split into groups of 68 and assigned to receive either a
probiotic or placebo for a period of 12 weeks. All participants received the same dietary
recommendations in order to reduce variation apart from the intervention. All
participants were instructed to stop the use of any probiotic containing food and
maintain their fiber intake two weeks prior to the start of the study and throughout the
duration. Each patient fasted for 10-12 hrs prior to every evaluation and laboratory
draw. The intervention consisted a powder containing six bacterial strains: Lactobacillus
acidophilus, Lactobacillus casei, Lactobacillus lactis, Bifidobacterium bifidum,
Bifidobacterium longum, and Bifidobacterium infantis. The powder was mixed into a
glass of water and consumed morning and evening each day. Compliance was
enforced by asking patients to bring their package of powder to each assessment for
evaluation.
Glycemic control, anthropometry, BMI, lipid profile, blood pressure, high
sensitivity CRP, and fecal samples were collected at baseline, 6 weeks, and 12 weeks.
Statistical analysis of the data included intention to treat and per protocol formats.
Results
The study screened 6976 patients and selected 456 as eligible after which 136
agreed to participate. The participants were 52.2% male and groups were comparable
in BMI (p=0.419) and oral antidiabetic medication (p=0.144). After 12 weeks, 20.6%
dropped out of the study and 25.7% of the participants were classified as noncompliant, but were included in the study. According to per protocol analysis 48
participants from the treatment group completed the study and 53 from the placebo
group.
The HbA1c slightly increased in the placebo group (-0.02± 0.56) and decreased
(0.14 ± 0.41%) in the probiotic group. Additionally the mean insulin levels were
significantly different between the two groups. These results were significant between

the two groups as seen in Table 1 below, but FBG had no significant changes
throughout the duration of the study. The results for FBG varied widely as both the
probiotic (-0.1± 1.5) and placebo (0.3±2.1) groups had unclear trends with large margins
for error.

Table 1. Change in glycemic variables.

Critique
The randomized, double blind design and inclusion of both per-protocol and
intention to treat analyses are strengths of this study. However, the randomization of
participants was performed by the lead researchers and not a third person, which draws
some concern. The total number of participants was the highest among the selected
studies lending more statistical power to its results. Of note, this study focuses on the
per-protocol results as these showed statistical significance. This is noted in Table 1 as
the change in HbA1c is only significant in the per-protocol analysis, and not in the
intention to treat analysis. In the discussion of the results the researchers neglect to
mention that the most appropriate analysis of results should focus on intention to treat
results and not per-protocol as the researchers take more liberty in deciding which
participants or data points are included in the assessment.
Despite the design elements seeking to reduce variability between groups the
researchers note that FBG is difficult to alter in well controlled patients with diabetes
due to the variables introduced by uncontrolled factors such as different levels of
physical activity and duration of fasting.
Finally, the study length is of concern when glycemic measurements such as
HgA1c are used. These laboratory values are known to take months to fully adjust to
changes in treatment or medication and a 12-week study may be insufficient to fully
realize the impact of probiotics.
Study 2
Probiotic yogurt improves antioxidant status in type 2 diabetic patients
Ejtahed et al. 201110
Objective

To determine the effect of probiotic-laced yogurt on blood glucose and
antioxidant status in patients with type 2 diabetes and on oral medication compared to
conventional yogurt.
Design
This study was a six week, randomized, double-blind, controlled clinical trial of
64 patients 30-60 years-old with at least a year-old diagnosis of T2DM recruited from an
endocrinology clinic in Iran. Exclusion criteria included patients using insulin,
cholesterol lowering medications, diuretics, or exogenous hormones, pregnant or
breastfeeding patients, or patients with kidney, liver or inflammatory disease, thyroid
disorders, immunodeficiency, or lactose intolerance. Patients were matched on sex and
age and randomized into two groups containing 32 participants each. The control group
received conventional yogurt with Lactobacillus bulgaricus and Streptococcus
thermophilus cultures (present in standard yogurts), and the interventional group
received an identical container of yogurt which contained L. Bulgaricus and S.
Thermophilus as well as B Lactis Bb12 and L. acidophilus La5 cultures. There was a
one-week run-in period where participants were instructed to not eat yogurt or other
fermented foods. Participants were then given a week’s supply of yogurt at a time and
instructed to keep it refrigerated. Consumption compliance was monitored by a weekly
telephone call. Three-day food diaries were conducted at the beginning and end of the
study. Anthropometric measurement and 12 hour fasting blood samples were taken at
the beginning and end of the trial.
Results
Per protocol results are based on 60 participants as four patients were excluded
for changing medication during the trial or for not following protocol (30 participants for
each group). The only statistically significant difference between the control and
intervention group pre-study was the time from diagnosis. The intervention group on
average had diabetes for 5.82 years (± 4.95 years) compared to the control group that
had diabetes on average for 4.08 years (± 4.28 years) (P=0.039). There were no
significant differences in dietary intake before or during the trial between the two groups.
Fasting blood glucose and HbA1c significantly decreased in the intervention group
compared to the control group (P=0.009 and P=0.019,respectively). However, based
on the statistics, HbA1c did not significantly change for the intervention group
(P=0.230), but the control group’s HbA1c significantly increased (P=0.003) which

possibly led to the significant difference between the groups. See Table 2 for values.

Table 2- Effects of 6 weeks of probiotic and conventional yogurt consumption on blood glucose, HbA1c, insulin, and
oxidative stress markers

Critique
A strength of this study includes the RCT design and testing the activity of the
cultures after a week to ensure that the participants are always consuming live cultures.
Some concerns for this study include the per protocol analysis which, in a small sample
size, can overestimate the effectiveness of the treatment. Also, there might possibly be
a recall bias for the dietary consumption data; however, since the participants weren’t
initially matched based on diet or nutritional status before sorting, and the data wasn’t
stratified based on dietary information after the study, the only utility for the dietary
information was to prove the similarities of the two groups and a recall bias might not
have that much of a negative effect. There was no disclosure of conflicts of interest (one
author is associated with the Iranian dairy industry as stated on the title page though in
what capacity is unknown).
Study 3
Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative
stress in patients with type 2 diabetes.
Asemi et al 20133
Objective
To determine how multispecies probiotics affect the metabolic status and
oxidative stress of patients with T2DM.
Design
This study was an 8-week, double-blind, randomized control trial of 60 patients
35-70 years-old with a T2DM diagnosis recruited from a diabetes clinic in Kashan, Iran.
Exclusion criteria included usage of insulin or vitamin supplements, pregnancy, cocondition including chronic kidney, liver, lung or inflammatory diseases, heart valve
disease, or allergies. Patients were matched on age, sex, BMI and oral hypoglycemic
medications (type and dosage) and were assigned to the intervention or control group
with 30 participants each with a makeup of 9 males and 21 females for each group.

Patients were required to complete a 2-week run-in period prior to starting where they
were instructed to refrain from taking probiotic foods and complete a 3, nonconsecutive
day food diary. After the run-in period, participants were either given probiotic
supplement capsules or placebo capsules to take each day. Participants were to
continue their normal activity and dietary habits while occasionally completing 3-day
food diaries. The probiotic capsules contained L. acidophilus, L. casei, L. rhamnosus, L.
bulgaricus, Bifidobacterium breve, B. longum, Streptococcus thermophilus, and 100 mg
fructo-oligosaccharide with lactose as carrier substances. The placebo contained the
same substances besides the bacteria and was packed in identical capsules.
Consumption compliance was monitored by a once-weekly phone interview and the
food diaries. Anthropometric measurements and overnight fasting blood samples were
taken at the beginning and end of the study.
Results
Per protocol results are based on 54 participants after three patients from each
group were excluded for use of antibiotics, supplements, or insulin or a diagnosis of
chronic kidney disease. No significant differences were found between the intervention
and control groups at the beginning of the study for dietary consumption or biochemical
measures except for the HbA1c which was higher in the intervention group compared to
the control group (p = 0.007). At the end of the study, there was a statistically
significant difference between the intervention and control group for mean changes in
FBG (P=0.01). However, both FBGs increased. The FBG for the intervention group
increased by 1.6 (±6) mg/dL, however the FBG for the control group increased by 28.8
(±8.5) mg/dL. In this study, the probiotic appeared to prevent a rise in FBG instead of
lowering. HbA1c was decreased in the intervention group and increased in the control
group but neither change was statistically significant nor were the changes between
groups significant. See Table 3 for results.

Table 3-Within-group and between-group comparisons of metabolic profiles, hs-CRP, and biomarkers of oxidative
stress after supplementation

Critiques
The strengths of this study include the two-week run-in period with no probiotic
foods and the matching for multiple factors of the participants before randomization
ensures that there is less difference between the two groups. Some concerns include
the per protocol analysis leading to an overestimation of effect and the lack of
disclosures of conflicts of interest. The study states that a company who sells

probiotics provided the probiotics for the trial, but it is unclear whether this was a
“donation” or if they were purchased.
DISCUSSION:
In summary, FBG was found to be a variable indicator of improved glycemic
control with the use of probiotics. Firouzi et al. found no significant difference, Ejtahed
et al. found significant differences within the intervention group, and Asemi et al. stated
that it stabilized FBG compared to the increase seen in the control group. This may
indicate that probiotics are an ineffective tool in the management of T2DM as results
are inconclusive. The alternative is that FBG is a poor endpoint for the measurement of
glycemic control with the use of this intervention. FBG is highly variable based on the
duration of fasting, activity level, and many homeostatic metabolic functions. These
may be less impacted by probiotics whereas the postprandial glucose levels may be
more influential. A better method of measurement may be HbA1c, which is defined as a
mean blood sugar indicator over a period of about 120 days. 11 FBG contributes only
about 30% to the changes in HbA1c while postprandial contributes close to 70%. 12 Thus
probiotics could have minimal effect on FBG but if they significantly decrease
postprandial glucose the HbA1c could be decreased and glycemic control improved.
All three studies demonstrated consensus on statistically significant differences
in HbA1c after the use of probiotics, but clinically the results are questionable in clinical
significance when possible error is considered. The change was a decrease of less
than once percentage point in each of the studies. Most patients with diabetes are
looking for more significant drops to reach their HbA1c goals. While a promising start,
in order to fully explore the possibility of probiotic mediated reduction in HbA1c, longer
duration studies must be performed to determine if this will be a clinically significant
adjunct therapy. Firouzi et al. was the longest study which was carried out across 84
days, but the HbA1c is a measure across a period of 120 days. Thus, a study lasting at
least 120 days would more accurately reflect the impact probiotics may have on
glycemic control.
Furthermore, studies are needed to investigate the target population of this
clinical query. These studies were completed in Malaysia and Iran and in order to apply
this research into clinical practice in the United States, which is the goal of this review, it
would be better supported with results in a similar population. While treatment
guidelines and therapy are comparable between Iran, Malaysia, and the United States,
activity level, diet, and many other aspects of glycemic control vary widely across
different populations and thus the application of probiotics may look different in the US
compared to that of Iran or Malaysia.
While the results of the effects of probiotic usage on HbA1c are promising, there
needs to be further studies to determine if they would be a useful adjunct treatment for
patients with T2DM on oral medications. Some other considerations for future studies

include larger sample sizes, longer study durations, evaluating post-prandial blood
glucose levels as an endpoint, and the utilization of probiotics in fermented foods vs.
probiotic capsules.

CONCLUSION:
FBG is an inconclusive measure of improved glycemic control in the treatment of
T2DM with probiotics, but cannot be ruled out as a possible benefit as HbA1c uniformly
improved. Postprandial glucose levels may be significantly impacted by the use of
probiotic supplements and is a target for future research. Research with a longer
duration is also needed to fully unveil the effect of probiotics on HbA1c. The benefits
offered in the use of probiotic supplements include improved glycemic control with little
side effects and ease of administration.
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